DCM
ACAD icon

DAFNA Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

DAFNA Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-83,000
Closed -$2.14M – 85
2021
Q1 		$2.14M Buy
+83,000
New +$3.65M 0.51% 47

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

DAFNA Capital Management's ACAD Position: Q2 2021 in Review

DAFNA Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 83,000 shares — an estimated $2.14M sold.

DAFNA Capital Management first reported a position in ACAD in Q1 2021 and held it in 1 quarter. The position peaked at $2.14M in Q1 2021. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • DAFNA Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 83,000 Acadia Pharmaceuticals shares in Q2 2021, an estimated $2.14M.
  • DAFNA Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • DAFNA Capital Management's Acadia Pharmaceuticals position peaked at $2.14M in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.